Barely Significant
← all excerpts

Targeted therapy in advanced <i>BRAF</i>-mutated colorectal cancer: systematic review and network meta-analysis.

BMJ · 2025 · PMC12628362 · PMID 41355781

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

did not reach statistical significanceno p-value reported
Adverse events —Anti-EGFR/BRAF was associated with a lower risk of grade ≥3 adverse events, although differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.